ANDAORALTABLET
Approved
Feb 2024
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
METHSCOPOLAMINE BROMIDE (methscopolamine bromide) by NERx Biosciences is clinical pharmacology methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. First approved in 2024.
Drug data last refreshed 1w ago
Mechanism of Action
CLINICAL PHARMACOLOGY Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacologic actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion,…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
NERx Biosciences
Worked on METHSCOPOLAMINE BROMIDE at NERx Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.